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Purpose: To evaluate whether Chlamydia (C.) infections are associated with age-related macular degeneration (AMD)
and to assess if this association is influenced by the complement factor H (CFH) Y402H or the high temperature
requirement A serine peptidase 1 (HTRA1) rs11200638 risk genotypes.
Methods: One hundred ninety-nine AMD patients with early and late forms of the disease and 100 unaffected controls,
at least 50 years old were included in the study. Patients in the AMD and control groups were selected based on known
CFH Y402H variant genotype status (one third homozygous CC, one third heterozygous CT, and one third wild-type TT).
Plasma from all patients and controls was tested for C. pneumoniae, C. trachomatis, and C. psittaci IgG seropositivity
using a micro-immunofluorescent assay to establish previous infection status. Assays were conducted blind to risk
genotypes and the results analyzed using univariate and multivariate (logistic regression) analysis.
Results: IgG seropositivity to C. pneumoniae was most prevalent (69.2%, n=207), followed by C. trachomatis (7.4%,
n=22) and C. psittaci (3.3%, n=10). No association was found between each of the three Chlamydia species IgG
seropositivity and AMD status or severity (early/late). There was also no significant association between Chlamydia
species IgG seropositivity and AMD status or severity, in patients carrying at least one CFH Y402H risk allele (C) or
HTRA1 rs11200638 risk allele (A), with univariate or logistic regression analysis.
Conclusions: Chlamydia infection status does not appear to be associated with AMD status or severity. The presence of
CFH Y402H and HTRA1 rs11200638 risk genotypes does not alter this negative association.
Age-related macular degeneration (AMD) is the leading
cause of severe visual impairment in developed countries [1,
2], affecting approximately 30–50 million people worldwide
(World  Health  Organization,  Visual  impairment  and
blindness). Environmental and genetic factors play a role in
AMD pathogenesis [3-8]. However, the exact biochemical
and cellular processes involved are not fully known. Several
reports  have  described  significant  associations  between
complement genes and susceptibility to AMD. The genes
include complement factor H (CFH) [9-12], complement 3
(C3) [13], high temperature requirement A serine peptidase 1
(HTRA1)  [14],  complement  factor  B  (CFB)  [15],  and
complement factor H-related 1+3 (CFHR1+CFHR3) [16,17].
A previous meta-analysis showed a 35% prevalence of the
CFH Y402H (rs1061170, T→C) risk allele (C) in AMD. This
increased the risk of AMD significantly (odds ratios of 2.5 and
6.3 for the heterozygous CT and homozygous CC genotypes,
respectively) with an estimated population risk of 59% [18].
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The association of CFH Y402H with AMD is intriguing
as the CFH protein is involved in regulating the alternative
complement pathway. By binding to C3b, the CFH protein
accelerates the decay of the alternative pathway convertase
C3bBb, and acts as a cofactor for complement factor I, another
C3b  inhibitor  [19,20].  Activation  of  the  alternative
complement  pathway  is  normally  triggered  by  microbes,
including the Chlamydia species [21-23]. This suggests that
chronic low-grade Chlamydia infection in the presence of
abnormal  CFH  protein  production  may  lead  to  enhanced
alternative  complement  pathway  activation  in  the  retina,
therefore increasing an individual’s risk of developing AMD.
The Chlamydiae include three species that can infect
humans: Chlamydia (C.) pneumoniae, C. trachomatis, and C.
psittaci. Chlamydiae are obligate intracellular parasites, due
to their reliance on host metabolism. They are found in the
environment  as  non-active  stable  small  cells  known  as
elementary bodies (EB). These cells are able to bind to and
enter  host  epithelial  cells,  forming  larger  intracellular
reticulate bodies (RB). The RB then multiply, deriving energy
from  host  metabolic  processes,  to  form  a  cytoplasmic
inclusion. This inclusion can then release new EBs from the
host cell to infect other cells. Typically, Chlamydiae remain
in the host on a subclinical level on a prolonged basis [24].
Molecular Vision 2012; 18:29-37 <http://www.molvis.org/molvis/v18/a5>
Received 21 June 2011 | Accepted 5 January 2012 | Published 10 January 2012
© 2012 Molecular Vision
29C.  pneumoniae  causes  respiratory  tract  infections  in
humans, including pneumonia, bronchitis, pharyngitis, and
sinusitis. C. pneumoniae is transmitted airborne, human to
human.  It  is  extremely  prevalent,  with  30%–50%  of  the
population carrying C. pneumoniae antibodies worldwide.
Only  one  species  of  C.  pneumoniae  has  been  described.
Chronic infection with C. pneumoniae has been associated
with AMD and other degenerative diseases (atherosclerosis
[25-29], cardiac valvular stenosis [30], Alzheimer disease
[31], and multiple sclerosis [32]). The association between C.
pneumoniae and AMD is not fully established in the literature.
Various studies, including preclinical and clinical studies,
have all shown contradictory results (see the summary in
Appendix  1)  [33-44].  In  addition,  the  association  of  C.
pneumoniae with CFH polymorphisms in AMD has not been
consistently replicated [40,42,45].
C. trachomatis can cause a range of diseases in humans,
including trachoma, inclusion conjunctivitis, non-gonococcal
urethritis,  salpingitis,  cervicitis,  and  lymphogranuloma
venereum. C. trachomatis is transmitted person to person,
including by sexual contact and from mother to baby during
delivery. At least 15 antigen-specific species (“serovars”) of
C. trachomatis have been described, including B, Ba, C-K,
and L1-L3 [24]. The prevalence of C. trachomatis in a general
European population aged 15–40 is around 3% [46], but can
be up to 17% in young women [47]. C. trachomatis is endemic
in poorer countries, where it is a leading cause of blindness
through  trachoma.  Only  one  study  has  investigated  the
association between C. trachomatis and AMD but found no
association [33]. No study has examined the association with
the CFH genotype and C. trachomatis in AMD.
The  natural  hosts  for  C.  psittaci  are  birds,  especially
parrots and parakeets. C. psittaci can be transmitted via bird
excretions to humans, causing a disease known as psittacosis,
which  primarily  causes  atypical  pneumonia.  At  least  four
serovars of C. psittaci have been described [24]. C. psittaci
prevalence in the general population is the least common of
the Chlamydia species, but is typically more common in bird
handlers  [48].  No  studies  have  as  yet  investigated  the
association between C. psittaci and AMD.
In this study, we investigated the association of all three
Chlamydia species (C. pneumonia, C. trachomatis, and C.
psittaci) with the CFH Y402H AMD risk variant in AMD. We
also investigated the association of the Chlamydia species
with another genetic variant strongly associated with AMD,
the HTRA1 gene (rs11200638, G→A) [49]. The function of
this  gene  is  not  yet  known,  and  has  not  been  previously
associated with Chlamydia.
METHODS
Patients were selected from a preexisting database of AMD
and  control  patients.  Selection  was  restricted  to  those  of
Caucasian origin, at least 50 years old, and with confirmed
genotyping [50]. Recorded height and weight were used to
calculate body mass index (BMI). All patients were recruited
under UK National Research Ethics Service approval, and had
previously given full informed consent.
AMD  status  was  determined  according  to  the  Age-
Related Eye Disease Study (AREDS) grading system using
clinical examination, stereoscopic fundus photographs, and
fluorescein angiography (Topcon TRC50IX) [51]. AREDS
grades  1–4  corresponded  to  AMD.  AREDS  grades  1–3
corresponded to early AMD, and AREDS 4 to late/advanced
AMD.
Patients were selected based on AMD and CFH Y402H
genotype status. In the AMD and control groups, one third of
patients  carried  the  homozygous  (CC)  risk  CFH  Y402H
genotype, one third the heterozygous (CT) genotype, and the
remaining one third the wild-type (TT) genotype. This was
done to facilitate comparisons between genotypes. DNA was
previously extracted using the salting-out method [52], and
stored at −20 °C. CFH Y402H [50] and HTRA1 rs11200638
genotype  status  were  determined  using  TaqMan  allelic
discrimination assay probe kits on an Applied Biosystems
3730  Genetic  Analyzer  (Life  Technologies  Corporation,
Carlsbad, CA).
Determining plasma Chlamydia serology: Stored plasma
samples were used for Chlamydia serology testing. These
samples  were  previously  obtained  by  collecting  10  ml  of
peripheral blood in lithium heparin tubes. These were then
centrifuged within a few hours at 1,300 xg for 10 min, and the
supernatant stored at −80 °C until analysis. Defrosted plasma
samples  were  tested  for  the  presence  of  Chlamydia  IgG
antibodies toward C. pneumoniae, C. trachomatis, and C.
psittaci using a micro-immunofluorescent (MIF) assay kit
(Focus  Diagnostics,  Cypress,  CA).  MIF  is  considered  the
laboratory gold standard for serological testing [53]. The IgG
assay was selected as it indicates any previous Chlamydia
infection and although titers do decrease after infection, the
rate of decline is minimal.
The MIF assay was a two-stage “sandwich” procedure,
using slides enclosed with the kit containing pretreated wells.
A single well contained four individual spots. Three of these
spots  contained  EBs  of  each  Chlamydia  species  (each
incorporating one strain of C. pneumoniae, two strains of C.
psittaci, and eight serotypes (D-K) of C. trachomatis), diluted
in 3% yolk sac (to provide background contrast). The fourth
spot was composed of yolk sac alone and acted as a control.
Each plasma sample was diluted 1:16 with phosphate buffered
saline (PBS 0.01 M, containing sodium chloride 137 mM,
phosphate buffer 10 mM, potassium chloride 2.7 mM), and
25 µl added to each well. The slide was covered and incubated
at room temperature for 60 min. The slide was then washed
with PBS for 10 min to remove unbound plasma antibodies,
dipped in distilled water, and then air-dried. Twenty-five µl
of fluorescein-labeled anti-IgG antibody was then added to
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30each well. The slide was covered and re-incubated at room
temperature for 30 min. The slide was then washed twice (as
before). “Mounting medium” (supplied with the kit) was then
added to the slide, and wells viewed using a fluorescence
microscope  at  400×  magnification.  Positive  reactions
appeared green, indicating fluorescent EBs on a background
of yolk sac (Figure 1). A positive result was confirmed when
the observed fluorescence level in any of the EB-containing
spots was greater than that seen in the corresponding control
yolk  sac,  no  matter  how  minimal  this  difference  was.  A
negative  result  was  confirmed  when  there  was  no
fluorescence, or the fluorescence equalled that observed in the
corresponding yolk sac control spot or in the negative control
well.  Any  samples  with  positive  tests  for  all  three
Chlamydiae species were retested for verification.
The sensitivity and specificity of this test for detecting C.
pneumoniae IgG seropositivity were specified as 62.5% and
99.8%,  respectively;  the  corresponding  values  for  C.
trachomatis  and  C.  psittaci  were  not  available  (Focus
Diagnostics,  Chlamydia  MIF  IgG  assay  instructions).  All
assays were performed blind to patient AMD CFH/HTRA1
genotype status.
Statistics:  One  hundred  and  ninety-nine  patients  with
early and late AMD, and 100 controls without AMD were
selected. Univariate analysis of differences between the AMD
and control groups were performed using the χ2 test (and
Fisher  Exact  test  when  appropriate)  for  categorical  data.
Continuous  data  was  analyzed  using  the  Student  t  test.
Multivariate  analysis  was  performed  using  binary  logistic
regression  to  assess  whether  covariates  (including  CFH
Y402H/HTRA1 genotype status, Chlamydia species serology
status,  age,  sex,  and  BMI)  could  predict  AMD  status  or
severity. The level of statistical significance in the study was
defined as p<0.05. When Chlamydia species were compared,
a  p  value  of  <0.0167  was  used  to  determine  statistical
significance, taking into account the Bonferroni correction for
multiple testing. All statistical analyses were performed using
SPSS (version 18.0, IBM, New York, NY).
RESULTS
Baseline  demographics  and  prevalence  of  Chlamydia
infection: Baseline demographics are described in Table 1.
Compared to controls, patients with AMD were older (78.3
versus  75.6  years,  p=0.009),  with  a  higher  proportion  of
women  (72.9%  versus  56%,  p=0.003).  Overall,  C.
pneumoniae  infection  was  common  (69.2%),  whereas  C.
trachomatis and C. psittaci were less prevalent (7.4% and
3.3%, respectively). There was no difference in age between
seropositive and seronegative patients, for C. pneumoniae
(78.1±8.1  versus  78.6±8.6,  p=0.688)  and  C.  trachomatis
(80.1±6.3  versus  78.1±8.4,  p=0.344),  although  patients
seropositive  for  C.  psittaci  were  older  (84.0±8.0  versus
78.0±8.2,  p=0.044).  There  was  also  no  difference  in  age
between patients with early versus late AMD (Table 2).
Chlamydia and AMD: Univariate analysis demonstrated no
statistical association between IgG seropositive status for all
three  Chlamydia  species  and  AMD  status.  A  subgroup
analysis of the AMD group also demonstrated no association
between Chlamydia species seropositivity and AMD severity
(early or late; Table 2).
Chlamydia and CFH genotype: No association was found
between Chlamydia species seropositivity and CFH Y402H
polymorphism, either when comparing genotypes (TT versus
CT versus CC) or the presence or absence of the risk allele (C;
Table 3). There was also no association between Chlamydia
species seropositivity and AMD status or severity in those
carrying the CFH Y402H risk allele (C; Table 4).
Chlamydia and HTRA1: We also looked at patients carrying
at least one HTRA1 rs11200638 risk allele (A) to explore any
association with Chlamydia seropositivity status and AMD.
There  was  no  association  with  Chlamydia  species
seropositivity and AMD status or severity in this group (Table
5).
Chlamydia, CFH genotype, and AMD: Multivariate logistic
regression analysis was then performed to identify covariates
that could predict AMD status or severity. C. trachomatis and
C. psittaci status was not included as covariates since IgG+
status was of low prevalence overall. When covariates were
Figure 1. Positive and negative results
from the MIF assay. The figure shows a
spot within a well with positive (A) and
negative  (B)  C.  pneumoniae  IgG
seroreactivity  as  tested  in  this  study
using the Focus Diagnostics MIF assay
(100× magnification).
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31restricted  to  C.  pneumoniae  IgG  status  (positive  versus
negative) and CFH Y402H genotype (CC versus CT versus
TT), C. pneumoniae IgG status was not predictive of AMD
status (p=0.842) or AMD severity (p=0.078). The outcome
was similar when the presence of the CFH Y402H risk allele
(C: present versus absent) was used as a covariate instead of
the CFH genotype.
Controlling for multiple variables (C. pneumoniae IgG
status,  age,  gender,  BMI,  CFH  Y402H  genotype,  HTRA1
rs11200638 genotype), logistic regression analysis indicated
predictors for AMD status included increased BMI (p=0.015,
OR 1.08, 95% CI: 1.01–1.14), increased age (p=0.015, OR
1.04, 95% CI: 1.01–1.08), female gender (p=0.011, OR 2.04,
95% CI: 1.18–3.51), and HTRA1 rs11200638 homozygous
TABLE 1. DEMOGRAPHIC DATA AND CHLAMYDIA SPECIES SEROPOSITIVITY STATUS IN ALL PATIENTS AND AMD VERSUS CONTROLS
Demographic data and Chlamydia IgG
+ve status
Total Control AMD p value (AMD versus
non-AMD)
Number 299 100 199  
Age (mean years±SD) 77.4 (±8.4) 75.6 (±8.4) 78.3 (±8.2) 0.009 #
Sex–males (%, n) 32.8% (98) 44.0% (44) 27.1% (54) 0.003 #
BMI (mean±SD, kg/m  ; total n=295) 26.3 (±4.8) 25.7 (±5.0) 26.6 (±4.7) 0.148
C. pneumoniae IgG+ve (%, n) 69.2% (207) 70% (70) 68.8% (137) 0.838
C. trachomatis IgG+ve (%, n) 7.4% (22) 5.0% (5) 8.5% (17) 0.268
C. psittaci IgG+ve (%, n) 3.3% (10) 2.0% (2) 4.0% (8) 0.504*
AMD=Age-related macular degeneration, BMI=Body mass index, C.=Chlamydia #: Statistically significant NB: Student t-test
         (continuous variables)/χ2 test (categorical variables) performed for all comparisons, except for those indicated by * (Fisher test
         used). P values for Chlamydiae species seropositivity associations are uncorrected.
TABLE 2. CHLAMYDIA SPECIES SEROPOSITIVITY STATUS IN EARLY VERSUS LATE AMD
Demographic data and Chlamydia IgG
+ve status
Early AMD Late AMD p value (early versus
late AMD)
Number 53 146  
Age (mean years±SD) 77.4 (±9.8) 78.6 (±7.6) 0.372
C. pneumoniae IgG+ve (%, n) 58.5% (31) 72.6% (106) 0.057
C. trachomatis IgG+ve (%, n) 7.5% (4) 8.9% (13) 0.762 *
C. psittaci IgG+ve (%, n) 7.5% (4) 2.7% (4) 0.127 *
         AMD=Age-related macular degeneration, C.=Chlamydia NB: Student t-test (continuous variables)/χ2 (categorical variables)
performed for all comparisons, except for those indicated by * (Fisher test used). P values for Chlamydiae species seropositivity
         associations are uncorrected.
TABLE 3. ASSOCIATION OF CHLAMYDIA SPECIES SEROPOSITIVITY STATUS AND CFH GENOTYPE
Chlamydia IgG +ve status CFH Y402H status % IgG +ve p value
C. pneumoniae IgG+ve (%,n) TT 64.6% (66)  
  CT 70.0% (70) 0.434
  CC 73.0% (73)  
  C allele 71.5% (143) 0.227
C. trachomatis IgG +ve (%,n) TT 8.1% (8)  
  CT 8.0% (8) 0.816
  CC 6.0% (6)  
  C allele 7.0% (14) 0.736
C. psittaci IgG +ve (%,n) TT 2 (2.0%)  
  CT 4 (4.0%) 0.669*
  CC 4 (4.0%)  
  C allele 8 (4.0%) 0.370*
         CFH=Complement Factor H gene, C.=Chlamydia NB: χ2 test performed for all comparisons, except for those indicated by *
         (Fisher test used). P values for Chlamydiae species seropositivity associations are uncorrected.
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2(AA) status (p=1.45×10−4, OR 11.05, 95% CI 3.20–38.17).
Again, C. pneumoniae IgG+ve status (p=0.768) was not a
predictor of AMD status.
We then performed logistic regression to predict whether
these same covariates (C. pneumoniae IgG status, age, gender,
BMI, CFH Y402H genotype, HTRA1 rs11200638 genotype)
were  predictors  of  AMD  severity.  The  only  positive
association in this model was CFH Y402H heterozygous (CT)
status, associated with late AMD (p=0.006, OR 3.43, 95% CI
1.42–8.27).
DISCUSSION
In this study, there was no association with Chlamydia species
seropositivity  and  AMD  status  or  severity,  either
independently or when taking into account CFH and HTRA1
risk genotypes, in addition to other variables (age, gender,
BMI).
Only  one  previous  study  has  reported  a  similar
retrospective  case-control  study  to  ours,  examining  the
association of C. pneumoniae status with CFH genotype on
AMD status. Shen et al. looked at 148 AMD patients and 162
controls, and found an association between C. pneumoniae
and AMD (OR 2.17, p<0.017), but not when a CFH risk
genetic variant was taken into account. However, important
differences exist between this study and ours. AMD patients
were included if they had late AMD only (geographic atrophy/
CNV), C. pneumoniae status was determined with PCR to
identify C. pneumonia DNA in peripheral blood cells, and the
rs380390 CFH single nucleotide polymorphism was selected
as  the  risk  CFH  genotype.  Furthermore,  there  was  no
comparison between AMD subtypes based on severity [42].
Haas  et  al.  also  performed  a  case-control  study  with  75
patients with AMD (any stage) and 75 controls, using enzyme-
linked  immunosorbent  assay  (ELISA)  to  determine  C.
pneumoniae seropositivity status. They found no association
between C. pneumoniae seropositivity and AMD, or between
C. pneumonia and the CFH Y402H genotype. This study did
not perform further analysis of C. pneumoniae together with
CFH genotype status in AMD due to insufficient numbers
[41]. Baird et al. performed a prospective study following up
233 patients over a mean of seven years. The authors found
patients  were  more  likely  to  progress  if  serum  C.
pneumoniae IgG levels, as measured with ELISA, were at the
upper tertile (42.5%) compared to the lower tertile (20.8%).
They also found an additive risk of AMD progression in
patients with the CFH Y402H risk allele (C) and upper tertile
of C. pneumoniae titers (OR 11.8, p=0.005) compared to those
with T allele and lowest C. pneumoniae titer [40].
Far less has been reported on the association of the other
two Chlamydia species and AMD, which may be a reflection
of the lower prevalence in the developed world. Kayalagu et
al. performed a small case-control study looking at serum
levels of C. trachomatis heat shock protein in 25 patients with
AMD and 13 controls, and found no association [33]. Our
study reached the same conclusions with a comparatively
larger sample size, and additionally found no association with
TABLE 4. CHLAMYDIA SPECIES SEROPOSITIVITY STATUS AND AMD STATUS/SEVERITY IN CFH Y402H C ALLELE CARRIERS
 
CFH Y402H risk C allele present






p value (early versus
late AMD)
C. pneumoniae +ve (%, n) 70.1% (47) 72.2% (96) 0.724 60.0% (18) 75.7% (78) 0.091
C. trachomatis +ve (%, n) 6.0% (4) 7.5% (10) 0.686* 6.7% (2) 7.8% (8) 1.000*
C. psittaci +ve (%, n) 1.5% (1) 5.3% (7) 0.272  * 13.3% (4) 2.9% (3) 0.045*
         AMD=Age-related macular degeneration, CFH=Complement Factor H gene, C.=Chlamydia NB: χ2 test performed for all
         comparisons, except for those indicated by * (Fisher test used). P values for Chlamydiae species seropositivity associations are
         uncorrected.
TABLE 5. CHLAMYDIA SPECIES SEROPOSITIVITY STATUS AND AMD STATUS/SEVERITY IN HTRA1 RS11200638 A ALLELE CARRIERS
  HTRA1 risk A allele present







Late AMD (n=91) p value (early
versus
late AMD)
C. pneumoniae +ve (%, n) 72.1% (31) 69.7% (85) 0.765 67.8% (21) 70.3% (64) 0.787
C. trachomatis +ve (%, n) 7.0% (3) 11.5% (14) 0.563* 12.9% (4) 11.0% (10) 0.751*
C. psittaci +ve (%, n) 0% (0) 3.3% (4) 0.574* 9.7% (3) 1.1% (1) 0.050*
         AMD=Age-related macular degeneration, C.=Chlamydia NB: χ2 test performed for all comparisons, except for those indicated
         by * (Fisher test used). P values for Chlamydiae species seropositivity associations are uncorrected.
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33AMD  risk  genotype.  No  studies  have  investigated  the
association of C. psittaci and AMD. Although our study found
no association between C. psittaci seropositivity and AMD,
the low prevalence highlights the difficulty of studying this
microorganism.
The prevalence of previous Chlamydia infection in this
study group was higher for all three species compared to
published data. This finding may reflect false positives from
the MIF assay, or may indicate Chlamydia species prevalence
rates  are  population-specific.  PCR  does  have  a  higher
specificity and sensitivity as a test for Chlamydia species, but
was  not  chosen  due  to  its  reliance  on  the  presence  of
Chlamydia DNA in the peripheral blood. Serological tests
enable any previous infection to be detected, which was our
aim.  Serological  techniques  include  complement  fixation,
indirect immunofluorescent assays, and ELISAs. The MIF
test was chosen since it is considered the “gold standard” of
Chlamydia serology testing [54]. Drawbacks of this method
include the dependence on the binding antigen used, as well
as variability in the experience and subjectivity of the person
reading and interpreting the results [55]. The use of purified
EBs  to  detect  species  and  serovar-specific  Chlamydia
antibodies means cross-reactivity does not happen often with
MIF  but  can  occur  especially  between  C.  psittaci  and  C.
pneumonia due to certain antigenic similarities [24,56].
In summary, Chlamydia infection status did not appear
to be associated with AMD status or with severity in this study.
The presence of CFH Y402H or HTRA1 risk genotypes did
not alter this negative association. The negative association
reported here is consistent with some previous reports but
ideally should be replicated in a larger AMD cohort.
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36Appendix 1. Association of C. pneumoniae with AMD - summary of results
from previously published studies.
To access the data, click or select the words “Appendix
1.” This will initiate the download of a compressed (pdf)
archive that contains the file. Abbreviations: Early AMD:
AMD  excluding  geographic  atrophy  (GA)/choroidal
neovascularisation (CNV), Advanced/late AMD: Presence of
GA/CNV, Wet AMD: Presence/past history of macular CNV,
Dry AMD: Presence of macular drusen /pigmentary change/
atrophy,  OR:  Odds  Ratio,  ELISA:  Enzyme-Linked
Immunosorbent  Assay,  IgG:  Immunoglobulin  G,  IHC:
Immuohistochemistry,  N/A:  Not  Applicable,  PCR:
Polymerase Chain Reaction.
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